

Change order details by crossing out unwanted information and writing in desired details/instructions. Place a line through the \boxtimes to remove the pre-checked option.

	DENOSUMAB (XGEVA) Therapy Plan To	Be Used In Infu	-	-	
Infusion Center Location:		Start D	Start Date:		
Diagno	sis/Indication:				
Authori	zation Number:				
Patient Name		DOB	Height	Weight	
Supp	ortive Care	Interva	I		
	DENOSUMAB 120 MG/1.7 ML (70 MG/ML) S	UBQ SOLN	Route:		
	Other, Starting when released, For 1 of Dose Frequency				
Labs		Interva	I		
	Comprehensive Metabolic Panel	Once			
	Starting when released				
	Treatment Lab Instructions	Every v	isit		
	Starting when released Nursing to re Draw labs 2 days Pre & Post This Planned	ase the following labs: -CMP, Provider approves to Release and Treatment Date.,			
Provi	der Communication Orders	Interva	Interval		
	Physician Communication	Once			
	Starting when released Order one CMP prior to patient beginning treatment.,				
	Provider Communication	Once			
	Starting when released Consider ora post-treatment hypocalcemia and bone pa		replacement in pati	ents who are at risk for	
Nursi	ng Orders	Interva	l		
	Nursing Communication	Every 2	8 days		
	Starting when released Remind patie cleaning.	ent of good dental hygie	ne and to avoid den	tal procedures other than	
Nursi	ng Communication	Interva	l		
	Nursing Communication	Every v	isit		
	Starting when released Use correcte Calcium (within last 30 days) was less tha last 30 days) is less than 8.5, and if Calciu provider. If patient's last Calcium lab draw	n 8.5, wait for Calcium I um still below 8.5 on sar	results. If previous conne day draw, hold tr	orrected Calcium (within eatment, and contact	
Emer	gency Medications	Interva	al		
	diphenhydrAMINE (BENADRYL) injection 25	5-50 mg PRN	Route: In	tramuscular	
	25 to 50 mg Once As Needed Intramusc headache, diaphoresis, fever, palpitations nausea, urticaria, chills, pruritis), For 1 do within 2 hours of reaction. Administer 25 r reaction doesn't resolve in 3 minutes may	, chest discomfort, bloo se, Administer 50 mg IN ng IM if patient has had	d pressure changes 1 if patient has NOT diphenhydramine w	(>/= 20 points in SBP), had diphenhydramine ithin 2 hours of reaction,	
	Provider Signature		voto	Timo	
	i tovidor olgitalare	EHR User ID D	ate	Time	
nitials					
		Page 1 of 2	EHRO)202-DT (06/27/2024)	
		DENOSU	MAB (XGEVA) MONTI	HLY INJECTION	
Place Patient Label Here			Prog & Orders		

2 puff Once As Needed Inhalation Wheezing, Sho contact provider. Administer with a spacer if available						
available.	, <u> </u>	······································				
methylPREDNISolone sod suc(PF) (Solu-MEDROL) injection 125 mg	PRN	Route: Intramuscular				
125 mg Once As Needed Intramuscular For shortness of breath for continued symptoms of mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes(>/= 20 points in SBP), nausea, urticaria, chills, pruritis) that worsen or persist 5 minutes after administration of diphenhydramine (Benadryl), and notify provider, Starting when released, Do not inject into deltoid.						
changes(>/= 20 points in SBP), nausea, urticaria, ch administration of diphenhydramine (Benadryl), and r	noresis, fever, pal hills, pruritis) that	pitations, chest discomfort, blood pressu worsen or persist 5 minutes after				
changes(>/= 20 points in SBP), nausea, urticaria, ch administration of diphenhydramine (Benadryl), and r	noresis, fever, pal hills, pruritis) that	pitations, chest discomfort, blood pressu worsen or persist 5 minutes after				

	Provider Signature	EHR User ID	Date	Time	
Initials					
		Page 2 of 2		EHR0202-DT (06/27/2024)	
		DENOSUMAB (XGEVA) MONTHLY INJECTION			
I	Place Patient Label Here	Prog & Orders			